74
Participants
Start Date
August 21, 2023
Primary Completion Date
May 31, 2026
Study Completion Date
October 31, 2026
GNS561 + Trametinib
GNS561: 50mg, 100mg, 150mg, 200mg and trametinib: 1mg, 1.5mg and 2mg
RECRUITING
Roswell Park Cancer Institute, Buffalo
WITHDRAWN
Hospital of the University of Pennsylvania, Philadelphia
RECRUITING
University of Virginia Comprehensive Cancer Center, Charlottesville
RECRUITING
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
RECRUITING
University Of Chicago Medical Center, Chicago
RECRUITING
University of Texas, MD Anderson Cancer Center, Houston
RECRUITING
USC Norris Comprehensive Cancer Center, Los Angeles
RECRUITING
LA Cancer Network, Los Angeles
RECRUITING
Pan American Center for Oncology Trials, LLC, Rio Piedras
Lead Sponsor
Genfit
INDUSTRY